Operations

Jeff Golfman, founder and president of Send 123, in a conversation with Pharmaceutical Executive, discusses how rising geopolitical tensions around Iran and broader global disruptions are reshaping pharmaceutical and medical supply chains.

Sanofi is appointing Belén Garijo chief as director and chief executive officer after its annual meeting, underscoring the company's leadership and governance changes.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Teva will acquire Emalex to add ecopipam, a late-stage pediatric Tourette syndrome candidate, ahead of a planned 2026 filing.

At Asembia AXS26, Clarivate’s Dee Chaudhary outlined how U.S. drug pricing policy is rapidly shifting, driving more aggressive payer utilization management, tightening access controls, and increasing volatility in pharmaceutical pricing and forecasting.

Sun Pharma is set to acquire Organon in a $11.75 billion deal, while IMG Pharma enters a definitive agreement to purchase Matsumoto, signaling continued global consolidation and portfolio expansion across the pharmaceutical industry.

AbbVie has announced a $1.4 billion investment to build a new pharmaceutical manufacturing campus in North Carolina, expanding its U.S. footprint with a focus on advanced sterile injectable production.

Supply chain chokepoints are converging to expose deep structural vulnerabilities in the U.S. drug supply, with new data showing that even medicines not currently in shortage may be one disruption away from crisis.

A new ICER white paper calls for reforms to the FDA’s accelerated approval pathway, citing ongoing challenges with regulatory consistency, confirmatory trial delays, and transparency.

Biotech financing activity this week underscores strong investor backing for platform-driven innovation, with capital flowing into ADC development, precision immunology, multi-cancer diagnostics, and non-invasive oncology technologies aimed at addressing persistent gaps in care.

Obsidian Therapeutics and Galera are merging to form a Nasdaq-listed cell therapy company backed by a $350 million private placement, aiming to advance OBX-115, a next-generation TIL therapy.

AbbVie entered a global licensing deal with Haisco worth up to $715 million to expand its pain pipeline with several assets.

Replimune received a second FDA complete response letter for RP1 in advanced melanoma, raising questions about the viability of its oncolytic immunotherapy program.

The U.S. government’s contract with Shionogi highlights renewed public-private investment in antimicrobial resistance and biodefense, aiming to strengthen domestic manufacturing and expand the role of novel antibiotics against high-priority threats.

Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.

Shah Capital escalates its pressure campaign against Novavax leadership, requesting changes and strategic overhauls amid ongoing performance concerns.

Companion diagnostics are reshaping precision oncology, but clinical adoption continues to lag behind scientific progress due to regulatory, operational and reimbursement barriers.

Disruptions from the U.S.and Iran conflict moves across key transit routes and threatens the flow of active ingredients, price spikes, and heightened risk of drug shortages worldwide.

BioNTech’s decision to close its Singapore manufacturing facility reflects mounting financial pressure, ongoing restructuring efforts, and uncertainty around the pace at which next-generation mRNA therapies will scale.

Neurocrine Biosciences’ planned $2.9 billion acquisition of Soleno Therapeutics includes the addition of Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome.

Pfizer and BioNTech halted a large U.S. clinical trial targeting healthy adults aged 50 to 64 after enrollment shortfalls made it impossible to generate the post-marketing data the FDA required.

Since the start of President Trump's second term, the FDA, CDC, CDER, and CBER have collectively cycled through more than a dozen leadership changes.

Eli Lilly warns that the UK's current framework is undermining investment and could impact future launches and manufacturing decisions.

The White House postponed naming a permanent CDC director as the Trump administration navigates competing political pressures ahead of midterm elections.

The deal adds OM336, a BCMAxCD3 bispecific T cell engager showing early efficacy in rare antibody-mediated autoimmune diseases, to Gilead's pipeline.